AF
BCRX icon

Advisornet Financial’s BioCryst Pharmaceuticals BCRX Stock Holding History

Advisornet Financial’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-259
Closed -$1.97K – 1991
2024
Q3 		$1.97K Hold
259
– – ﹤0.01% 1759
2024
Q2 		$1.6K Hold
259
– – ﹤0.01% 1678
2024
Q1 		$1.32K Sell
259
-17
-6% -$96 ﹤0.01% 1695
2023
Q4 		$1.65K Buy
276
+9
+3% +$52 ﹤0.01% 1764
2023
Q3 		$1.89K Sell
267
-11
-4% -$79 ﹤0.01% 1651
2023
Q2 		$1.96K Sell
278
-2
-0.7% -$16 ﹤0.01% 1724
2023
Q1 		$2.33K Buy
280
+14
+5% +$135 ﹤0.01% 1664
2022
Q4 		$3.05K Buy
266
+7
+3% +$87 ﹤0.01% 1576
2022
Q3 		$3K Hold
259
– – ﹤0.01% 1591
2022
Q2 		$3K Sell
259
-1,500
-85% -$15.5K ﹤0.01% 1597
2022
Q1 		$29K Hold
1,759
– – ﹤0.01% 1131
2021
Q4 		$24K Hold
1,759
– – ﹤0.01% 1240
2021
Q3 		$25K Hold
1,759
– – ﹤0.01% 1190
2021
Q2 		$28K Hold
1,759
– – ﹤0.01% 1141
2021
Q1 		$18K Buy
1,759
+259
+17% +$2.67K ﹤0.01% 1214
2020
Q4 		$11K Buy
+1,500
New +$7.73K ﹤0.01% 1258
2019
Q4 		– Sell
-500
Closed -$1K – 1849
2019
Q3 		$1K Buy
+500
New +$1.55K ﹤0.01% 1725

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Advisornet Financial's BCRX Position: Q4 2024 in Review

Advisornet Financial sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2024, closing a stake of 259 shares — an estimated $1.97K sold.

Advisornet Financial first reported a position in BCRX in Q3 2019 and held it in 17 quarters. The position peaked at $29K in Q1 2022. 258 funds tracked by Wall St. Rank hold BCRX as of Q4 2024.

  • Advisornet Financial reported no remaining BioCryst Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Advisornet Financial sold 259 BioCryst Pharmaceuticals shares in Q4 2024, an estimated $1.97K.
  • Advisornet Financial first reported a position in BioCryst Pharmaceuticals in Q3 2019 and held it in 17 quarters.
  • Advisornet Financial's BioCryst Pharmaceuticals position peaked at $29K in Q1 2022.
  • 258 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2024.

Based on Advisornet Financial's 13F filing for Q4 2024, filed 13 Jan 2025.